Patents by Inventor Subrata Shaw

Subrata Shaw has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230330099
    Abstract: The present disclosure provides for compounds that inhibit the activity of an anti-apoptotic Bcl-2 family member Myeloid cell leukemia-1 (Mcl-1) protein. The present disclosure also provides for pharmaceutical compositions as well as methods for using compounds for treatment of diseases and conditions (e.g., cancer) characterized by the over-expression or dysregulation of Mcl-1 protein.
    Type: Application
    Filed: December 9, 2022
    Publication date: October 19, 2023
    Inventors: Taekyu Lee, James C. Tarr, KyuOk Jeon, James M. Salovich, Subrata Shaw, Nagarathanam Veerasamy, Kwangho Kim, Plamen P. Christov, Edward T. Olejniczak, Bin Zhao, Stephen W. Fesik, Zhiguo Bian
  • Patent number: 11596639
    Abstract: The present disclosure provides for compounds that inhibit the activity of an anti-apoptotic Bcl-2 family member Myeloid cell leukemia-1 (Mcl-1) protein. The present disclosure also provides for pharmaceutical compositions as well as methods for using compounds for treatment of diseases and conditions (e.g., cancer) characterized by the over-expression or dysregulation of Mcl-1 protein.
    Type: Grant
    Filed: March 3, 2017
    Date of Patent: March 7, 2023
    Assignee: Vanderbilt University
    Inventors: Taekyu Lee, James C. Tarr, KyuOk Jeon, James M. Salovich, Subrata Shaw, Nagarathanam Veerasamy, Kwangho Kim, Plamen P. Christov, Edward T. Olejniczak, Bin Zhao, Stephen W. Fesik, Zhiguo Bian
  • Publication number: 20230039309
    Abstract: The present invention provides for compounds that inhibit the activity of an anti-apoptotic Bcl-2 family member Myeloid cell leukemia-1 (Mcl-1) protein. The present invention also provides for pharmaceutical compositions as well as methods for using compounds for treatment of diseases and conditions (e.g., cancer) characterized by the over-expression or dysregulation of Mcl-1 protein.
    Type: Application
    Filed: November 4, 2021
    Publication date: February 9, 2023
    Inventors: Taekyu Lee, Zhiguo Bian, Johannes Belmar, Plamen P. Christov, Nicholas F. Pelz, Subrata Shaw, Kwangho Kim, James C. Tarr, Edward T. Olejniczak, Bin Zhao, Stephen W. Fesik
  • Patent number: 11208415
    Abstract: The present invention provides for compounds that inhibit the activity of an anti-apoptotic Bcl-2 family member Myeloid cell leukemia-1 (Mcl-1) protein. The present invention also provides for pharmaceutical compositions as well as methods for using compounds for treatment of diseases and conditions (e.g., cancer) characterized by the over-expression or dysregulation of Mcl-1 protein.
    Type: Grant
    Filed: November 19, 2019
    Date of Patent: December 28, 2021
    Assignee: Vanderbilt University
    Inventors: Taekyu Lee, Zhiguo Bian, Johannes Belmar, Plamen P. Christov, Nicholas F. Pelz, Subrata Shaw, Kwangho Kim, James C. Tarr, Edward T. Olejniczak, Bin Zhao, Stephen W. Fesik
  • Publication number: 20210283138
    Abstract: The present disclosure provides for compounds that inhibit the activity of an anti-apoptotic Bcl-2 family member Myeloid cell leukemia-1 (Mcl-1) protein. The present disclosure also provides for pharmaceutical compositions as well as methods for using compounds for treatment of diseases and conditions (e.g., cancer) characterized by the over-expression or dysregulation of Mcl-1 protein.
    Type: Application
    Filed: March 3, 2017
    Publication date: September 16, 2021
    Inventors: Taekyu Lee, James C. Tarr, KyuOk Jeon, James M. Salovich, Subrata Shaw, Nagarathanam Veerasamy, Kwangho Kim, Plamen P. Christov, Edward T. Olejniczak, Bin Zhao, Stephen W. Fesik, Zhiguo Bian
  • Publication number: 20200140447
    Abstract: The present invention provides for compounds that inhibit the activity of an anti-apoptotic Bcl-2 family member Myeloid cell leukemia-1 (Mcl-1) protein. The present invention also provides for pharmaceutical compositions as well as methods for using compounds for treatment of diseases and conditions (e.g., cancer) characterized by the over-expression or dysregulation of Mcl-1 protein.
    Type: Application
    Filed: November 19, 2019
    Publication date: May 7, 2020
    Inventors: Taekyu Lee, Zhiguo Bian, Johannes Belmar, Plamen P. Christov, Nicholas F. Pelz, Subrata Shaw, Kwangho Kim, James C. Tarr, Edward T. Olejniczak, Bin Zhao, Stephen W. Fesik
  • Patent number: 10533010
    Abstract: The present invention provides for compounds that inhibit the activity of an anti-apoptotic Bcl-2 family member Myeloid cell leukemia-1 (Mcl-1) protein. The present invention also provides for pharmaceutical compositions as well as methods for using compounds for treatment of diseases and conditions (e.g., cancer) characterized by the over-expression or dysregulation of Mcl-1 protein.
    Type: Grant
    Filed: March 26, 2015
    Date of Patent: January 14, 2020
    Assignee: Vanderbilt University
    Inventors: Taekyu Lee, Zhiguo Bian, Johannes Belmar, Plamen P. Christov, Nicholas F. Pelz, Subrata Shaw, Kwangho Kim, James C. Tarr, Edward T. Olejniczak, Bin Zhao, Stephen W. Fesik
  • Publication number: 20170174689
    Abstract: The present invention provides for compounds that inhibit the activity of an anti-apoptotic Bcl-2 family member Myeloid cell leukemia-1 (Mcl-1) protein. The present invention also provides for pharmaceutical compositions as well as methods for using compounds for treatment of diseases and conditions (e.g., cancer) characterized by the over-expression or dysregulation of Mcl-1 protein.
    Type: Application
    Filed: March 26, 2015
    Publication date: June 22, 2017
    Inventors: Taekyu Lee, Zhiguo Bian, Johannes Belmar, Plamen P. Christov, Nicholas F. Pelz, Subrata Shaw, Kwangho Kim, James C. Tarr, Edward T. Olejniczak, Bin Zhao, Stephen W. Fesik